Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Inventory (2021 - 2025)

Kiniksa Pharmaceuticals International's Change in Inventory history spans 5 years, with the latest figure at $13.5 million for Q4 2025.

  • For Q4 2025, Change in Inventory rose 682.86% year-over-year to $13.5 million; the TTM value through Dec 2025 reached $28.5 million, up 699.64%, while the annual FY2025 figure was $28.5 million, 699.64% up from the prior year.
  • Change in Inventory reached $13.5 million in Q4 2025 per KNSA's latest filing, up from -$6.8 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $26.1 million in Q2 2025 to a low of -$6.8 million in Q3 2025.
  • Average Change in Inventory over 5 years is $2.7 million, with a median of $1.1 million recorded in 2023.
  • Peak YoY movement for Change in Inventory: plummeted 583.23% in 2022, then soared 1322.14% in 2024.
  • A 5-year view of Change in Inventory shows it stood at -$1.9 million in 2021, then surged by 461.37% to $7.0 million in 2022, then dropped by 20.62% to $5.5 million in 2023, then plummeted by 141.81% to -$2.3 million in 2024, then soared by 682.86% to $13.5 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Change in Inventory are $13.5 million (Q4 2025), -$6.8 million (Q3 2025), and $26.1 million (Q2 2025).